EP3270963A4 - Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections - Google Patents

Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections Download PDF

Info

Publication number
EP3270963A4
EP3270963A4 EP16765794.9A EP16765794A EP3270963A4 EP 3270963 A4 EP3270963 A4 EP 3270963A4 EP 16765794 A EP16765794 A EP 16765794A EP 3270963 A4 EP3270963 A4 EP 3270963A4
Authority
EP
European Patent Office
Prior art keywords
vaccines
adjuvants
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16765794.9A
Other languages
German (de)
French (fr)
Other versions
EP3270963A2 (en
Inventor
Gary Eldridge
Steven M. Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sequoia Vaccines Inc
Original Assignee
Sequoia Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/660,523 external-priority patent/US9149521B2/en
Priority claimed from US14/800,003 external-priority patent/US9415097B2/en
Application filed by Sequoia Sciences Inc filed Critical Sequoia Sciences Inc
Publication of EP3270963A2 publication Critical patent/EP3270963A2/en
Publication of EP3270963A4 publication Critical patent/EP3270963A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
EP16765794.9A 2015-03-17 2016-03-17 Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections Withdrawn EP3270963A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14/660,523 US9149521B2 (en) 2013-09-25 2015-03-17 Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US201562135092P 2015-03-18 2015-03-18
US14/800,003 US9415097B2 (en) 2013-09-25 2015-07-15 Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
PCT/US2016/022977 WO2016149558A2 (en) 2015-03-17 2016-03-17 Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections

Publications (2)

Publication Number Publication Date
EP3270963A2 EP3270963A2 (en) 2018-01-24
EP3270963A4 true EP3270963A4 (en) 2018-08-22

Family

ID=56919421

Family Applications (2)

Application Number Title Priority Date Filing Date
EP16765693.3A Withdrawn EP3270962A4 (en) 2015-03-17 2016-03-16 Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
EP16765794.9A Withdrawn EP3270963A4 (en) 2015-03-17 2016-03-17 Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP16765693.3A Withdrawn EP3270962A4 (en) 2015-03-17 2016-03-16 Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections

Country Status (3)

Country Link
EP (2) EP3270962A4 (en)
CN (2) CN107405395A (en)
WO (2) WO2016149417A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199071A1 (en) * 2000-12-08 2003-10-23 Solomon Langermann Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
US20080131466A1 (en) * 2006-09-26 2008-06-05 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20130273149A1 (en) * 2012-04-12 2013-10-17 Ac Immune Sa Disaccharide synthetic lipid compounds and uses thereof
WO2015044886A2 (en) * 2013-09-25 2015-04-02 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE69937343T2 (en) * 1998-05-07 2008-07-24 Corixa Corp., Seattle ADJUVANEAN COMPOSITION AND METHODS OF USE THEREOF
WO2002015928A1 (en) * 2000-08-18 2002-02-28 Medimmune, Inc. METHOD OF ADMINISTERING FimH PROTEIN AS A VACCINE FOR URINARY TRACT INFECTIONS
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US9669060B2 (en) * 2009-04-23 2017-06-06 Cornell University Compositions for preventing and treating uterine disease
CA2767392C (en) * 2009-07-06 2017-03-14 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
ES2563730T3 (en) * 2009-07-15 2016-03-16 Glaxosmithkline Biologicals S.A. RSV F protein compositions and manufacturing processes thereof
TR201908003T4 (en) * 2012-02-07 2019-06-21 Infectious Disease Res Inst Advanced adjuvant formulations containing TLR4 agonists and their method of use.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199071A1 (en) * 2000-12-08 2003-10-23 Solomon Langermann Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
US20080131466A1 (en) * 2006-09-26 2008-06-05 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20130273149A1 (en) * 2012-04-12 2013-10-17 Ac Immune Sa Disaccharide synthetic lipid compounds and uses thereof
WO2015044886A2 (en) * 2013-09-25 2015-04-02 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANDERSON R C ET AL: "Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations", COLLOIDS AND SURFACES. B, BIOINTERFACES, ELSEVIER, AMSTERDAM, NL, vol. 75, no. 1, 1 January 2010 (2010-01-01), pages 123 - 132, XP026770794, ISSN: 0927-7765, [retrieved on 20090820], DOI: 10.1016/J.COLSURFB.2009.08.022 *
AYESHA MISQUITH ET AL: "In vitro evaluation of TLR4 agonist activity: Formulation effects", COLLOIDS AND SURFACES. B, BIOINTERFACES, vol. 113, 1 January 2014 (2014-01-01), NL, pages 312 - 319, XP055270242, ISSN: 0927-7765, DOI: 10.1016/j.colsurfb.2013.09.006 *
C. B. FOX ET AL: "Effects on Immunogenicity by Formulations of Emulsion-Based Adjuvants for Malaria Vaccines", CLINICAL AND VACCINE IMMUNOLOGY, vol. 19, no. 10, 1 October 2012 (2012-10-01), US, pages 1633 - 1640, XP055286524, ISSN: 1556-6811, DOI: 10.1128/CVI.00235-12 *
HW MILLIE FUNG ET AL: "Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activity", JOURNAL OF NANOBIOTECHNOLOGY, BIOMED CENTRAL, GB, vol. 11, no. 1, 21 December 2013 (2013-12-21), pages 43, XP021172581, ISSN: 1477-3155, DOI: 10.1186/1477-3155-11-43 *
LANGERMANN S ET AL: "VACCINATION WITH FIMH ADHESIN PROTECTS CYNOMOLGUS MONKEYS FROM COLONIZATION AND INFECTION BY UROPATHOGENIC ESCHERICHIA COLI", JOURNAL OF INFECTIOUS DISEASES. JID, UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, vol. 181, 1 February 2000 (2000-02-01), pages 774 - 778, XP002944650, ISSN: 0022-1899, DOI: 10.1086/315258 *
RHEA N. COLER ET AL: "Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant", PLOS ONE, vol. 6, no. 1, 26 January 2011 (2011-01-26), pages e16333, XP055030261, DOI: 10.1371/journal.pone.0016333 *

Also Published As

Publication number Publication date
WO2016149558A2 (en) 2016-09-22
EP3270962A1 (en) 2018-01-24
CN107405395A (en) 2017-11-28
EP3270962A4 (en) 2018-08-22
EP3270963A2 (en) 2018-01-24
WO2016149417A1 (en) 2016-09-22
CN107530418A (en) 2018-01-02
WO2016149558A3 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
EP3049104A4 (en) Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
EP3347469A4 (en) Methods and compositions for the treatment of glaucoma
HK1222398A1 (en) Compositions and methods for the treatment of burkholderia infections
EP3390666A4 (en) Compositions and methods for treatment of kidney diseases
EP3157565A4 (en) Treatment of polybacterials infections
EP3285874A4 (en) Compositions and methods for treating mycobacteria infections and lung disease
EP3280422A4 (en) Compositions and methods for the treatment of hbv infection
EP3268007A4 (en) Compositions and therapeutic methods for the treatment of complement-associated diseases
ZA201702884B (en) Compositions and methods for the treatment and prophylaxis of surgical site infections
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
EP3166615A4 (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
EP3442996A4 (en) Methods of treatment using chlorotoxin conjugates
HK1252343A1 (en) Compositions and methods for the treatment of viral infection
EP3518918A4 (en) Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
IL250596A0 (en) A composition for the treatment and prevention of urinary tract infections
EP3419638A4 (en) Compositions and methods of treatment of chronic infectious diseases
EP3426671A4 (en) Compounds and compositions for the treatment of infections
EP3452015A4 (en) Compositions and methods for treatment of inflammation or infection of the eye
EP3373922A4 (en) Compositions and methods for treatment of homocystinuria
EP3341006A4 (en) Compositions and methods for the treatment of neurodamage
EP3258908A4 (en) Compositions and methods for treatment of skin infections
EP3509614A4 (en) Methods and compositions for treatment of lafora disease
EP3538079A4 (en) Compositions and methods for the treatment of oral infectious diseases
EP3448377A4 (en) Methods for the treatment of infection
EP3362062A4 (en) Compositions and methods to treat urinary tract infections

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20171011

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20180719

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/02 20060101ALI20180713BHEP

Ipc: A61K 9/00 20060101ALI20180713BHEP

Ipc: A61K 39/108 20060101AFI20180713BHEP

Ipc: A61K 39/39 20060101ALI20180713BHEP

Ipc: A61K 39/00 20060101ALI20180713BHEP

Ipc: A61K 31/7016 20060101ALI20180713BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SEQUOIA VACCINES, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SEQUOIA VACCINES, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190219